Department of Pediatrics, Pediatric Heart Lung Center, University of Colorado School of Medicine, and The Children's Hospital, Aurora, CO, USA.
Pediatr Crit Care Med. 2010 Mar;11(2 Suppl):S4-9. doi: 10.1097/PCC.0b013e3181c765f3.
Pulmonary arterial hypertension in children contributes significantly to morbidity and mortality in diverse pediatric cardiac, lung, hematologic, and other diseases. Pulmonary arterial hypertension is generally a disease of small pulmonary arteries characterized by vascular narrowing due to high-tone and abnormal vasoreactivity, structural remodeling of the vessel wall, intraluminal obstruction, and decreased vascular growth and surface area. Without therapy, high pulmonary vascular resistance contributes to progressive right ventricular failure, low cardiac output, and death. Advances in basic pulmonary vascular biology over the last few decades have led directly to several novel therapies, which have significantly expanded therapeutic choices and have led to improved survival and quality of life of many children with pulmonary arterial hypertension. Despite these improvements, long-term outcomes in many settings remain guarded and substantial challenges persist, especially with regard to understanding mechanisms and approach to structural remodeling of severe pulmonary arterial hypertension.
儿童肺动脉高压会显著增加多种儿科心脏、肺部、血液疾病的发病率和死亡率。肺动脉高压通常是一种小肺动脉疾病,其特征是由于高音调异常血管反应性、血管壁结构重塑、管腔阻塞以及血管生长和表面积减少而导致血管狭窄。如果不进行治疗,高肺血管阻力会导致右心室衰竭、心输出量降低和死亡进行性加重。过去几十年中,基础肺血管生物学的进步直接导致了几种新的治疗方法,这极大地扩展了治疗选择,并显著提高了许多肺动脉高压儿童的生存率和生活质量。尽管取得了这些进展,但在许多情况下,长期预后仍不容乐观,仍然存在很大的挑战,特别是在理解严重肺动脉高压的发病机制和处理结构重塑方面。